Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck to Showcase Oncology Pipeline at Investor Day Amid Concerns About Dependence on Keytruda

With two new approvals for the vaunted checkpoint inhibitor Keytruda and a rapidly expanding oncology pipeline following M&A deals, Merck & Co. plans to share outlines for the future of the company’s cancer treatment at the first investor day held in five years.

Read More »

Rare Cancer Treatments and the Power of Checkpoint Inhibitors Among Hot Topics at ASCO

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.

Read More »

Synlogic Announces Clinical Collaboration with Roche

Synlogic Inc. announced a new clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine SYNB1891 – a dual innate immune activator engineered to express a STING agonist – in combination with Roche’s PD-L1-blocking checkpoint inhibitor atezolizumab (marketed as Tecentriq) in patients with advanced solid tumors.

Read More »

Dana-Farber Scientists Win Checkpoint Inhibitor Patent Lawsuit

Vaunted immunotherapy pioneers from the Dana-Farber Cancer Institute won a key court case that could be worth billions of dollars.

Read More »

Keytruda: Mixed Results in Gastric Cancer Study

Merck & Co. reported that the checkpoint inhibitor Keytruda had mixed results as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Read More »

Potential Cancer “Vaccine” Shows Promise in Early-Stage NHL Trial

Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine.

Read More »

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo in Previously Treated NSCLC Patients

Bristol-Myers Squibb Company announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab).

Read More »

Seattle Genetics & Astellas Report Positive Urothelial Cancer Study

Seattle Genetics and Tokyo-based Astellas Pharma announced positive top-line data from the first cohort of the Phase II EV-201 trial evaluating enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who had previously received both platinum-based chemotherapy and a checkpoint inhibitor.

Read More »

AbbVie’s Humira Remains Top-Selling Rx Drug for 2018

AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.

Read More »

Opdivo Plus Low-Dose Yervoy Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC

Bristol-Myers Squibb Company announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom